Abstract
Introduction: Radionuclide-labeled somatostatin analogs have proven to be effective in the treatment of inoperable metastatic neuroendocrine tumors. Since 2009 this therapy has been administered at the National Cancer Institute, allowing the adjustment of an optimized procedure for the administration of radionuclide therapy.
Objective: To present a clinical health care model for administration of Lutetium177 radiolabeled peptide therapy for gastroenteropancreatic neuroendocrine tumors, developed at the National Cancer Institute of Bogota, Colombia.
Methods: A health care model for patients with gastroenteropancreatic neuroendocrine tumors was structured. The present model is the result of adjustments and improvements in the process of care, updating of literature, and was designed to treat patients under clinical research and medical care models based on clinical determinants.
Results: A systematic and effective health care model was designed and implemented for Lutetium177-DOTA-TATE/DOTATOC therapy administration in patients with gastroenteropancreatic neuroendocrine tumors.
Conclusion: An optimized process of care based on clinical outcome determinants has been developed for patients receiving this type of radiometabolic therapy.
Key words: Neuroendocrine tumors, Receptors, somatostatin, Lutetium-177, Nuclear Medicine, Radiopharmaceuticals.
